# PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

> **NCT07232069** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Duke University** · enrollment: 1500 (estimated)

## Conditions studied

- Coronary Artery Disease Risk Factors Multiple
- Coronary Artery Disease Progression
- Prevention & Control
- Premature Atherosclerosis

## Interventions

- **DRUG:** Rosuvastatin 20 Mg Oral Tablet
- **DRUG:** Colchicine 0.5 MG Oral Tablet Once Daily
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07232069
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2031-07
- **Final completion:** 2031-07
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232069, "PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07232069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*